(19) World Intellectual Property Organization

International Bureau



T HOLD BUILDER IN DER IN DER BERN BERN EINE EINE EINE BERN BUILD BRICH BERN BERN BERN BERN BERN BERN BERN BER

(43) International Publication Date 21 July 2005 (21.07.2005)

PCT

(10) International Publication Number WO 2005/065689 A1

(51) International Patent Classification⁷: A61K 31/505, C07D 239/54, C07F 7/08, A61P 33/00, 33/06

(21) International Application Number:

PCT/GB2005/050002

(22) International Filing Date: 6 January 2005 (06.01.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0400290.3

8 January 2004 (08.01.2004) G

(71) Applicant (for all designated States except US): MEDI-VIR AB [SE/SE]; Lunastigen 7, S-141 44 Huddinge (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GILBERT, Ian [GB/GB]; Welsh School of Pharmacy, Cardiff University, Cardiff, Gwent CF1 0XF (GB). NGUYEN, Gorinne [FR/GB]; Welsh School of Pharmacy, Cardiff University, Cardiff, Gwent CF1 0XF (GB). RUDA, Gian, Filippo [IT/GB]; Welsh School of Pharmacy, Cardiff University, Cardiff, Gwent CF1 0XF (GB). SCHHIPANI, Alessandro [IT/GB]; Welsh School of Pharmacy, Cardiff University, Cardiff, Gwent CF1 0XF (GB). KASINATHAN, Ganasan [MY/GB]; Welsh School of Pharmacy, Cardiff University, Cardiff, Gwent CF1 0XF (GB). JOHANSSON, Nils-Gunnar [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). PACANOWSKA, Dolores, Gonzales [ES/ES]; Instituto de Parasitologia y Biomedicina, Consejo

Superior de Investigaciones Cientificas, C/Ventanilla 11, E-18001 Granada (ES).

- (74) Agents: TEUTEN, Andrew, J. et al.; Sagittarius Intellectual Property Consultants Ltd, Taylor House, 39 High Street, Marlow, Bucks SL7 1AF (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DUTPASE INHIBITORS

$$\begin{array}{c} R6 \\ R7-E-C_0-C_3-alkylene-D-C_0-C_3-alkylene \\ R8 \end{array}$$

(57) Abstract: Deoxyuridine derivatives of the formula (I) where R¹ is H or various substituents; D is -NHCO-, -CONH-, -0-, -C(=O)-, -CH=CH, -CΞC-, -NR⁵-; R⁴ is hydrogen or various substituents; R⁵ is H, C₁-C₄ alkyl, C₁-C₄ alkanoyl; E is Si or C; R⁶, R⁷ and R⁸ are independently selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl or a stable monocyclic, bicyclic or tricyclic ring system; G is -O-, -S-, -CHR¹⁰-, -C(=O)-; J is -CH₂-, or when G is CHR¹⁰ may also be -O- or -NH-; R¹⁰ is H, F, -CH₃, -CH₂NH₂, -CH₂OH, CH(OH)CH₃, CH(NH₃)CH₃; or R¹⁰ and R¹¹ together define an olefinic bond, or together form a -CH₂-group, thereby defining a *cis* or *trans* cyclopropyl group; have utility in the prophylaxis or treatment of protozoal diseases such as malaria.